Peptides, IV Hydration, GLP-1 Tirzepatide, Semaglutide, Retatrutide Certification
Beyond Injectables™:
Master the fastest-growing services in modern wellness medicine with Beyond Injectables™, the newest accredited CME courses built for nurses, nurse practitioners, PAs, and medical directors who want to run a safe, profitable, and defensible practice.
This first module covers comprehensive training in GLP-1 weight loss (semaglutide, tirzepatide, Wegovy, Zepbound, Ozempic, and Mounjaro), the top 20 marketed peptides, IV wellness therapy, and emerging weight loss agents including retatrutide and the new oral GLP-1s, so you understand every therapy your patients ask about. You will learn evidence-based prescribing, patient counseling, contraindication screening, compounding law (503A and 503B), scope of practice, and medical director liability, taught by a board-certified physician with a vendor-neutral, no-hype approach. Whether you are launching a wellness clinic or upgrading an existing one, this course gives you the clinical judgment and business framework to do it right.
Please note, this course is a PRE-SALE. Be among the first to receive and complete the first ever ACCME, AMA Category 1, and ANCC accredited course in this subject matter.
That means this is a course both an RN or NP, and your medical director can both take for direct certification credit.
Release date is September 1, 2026, or earlier upon CME credit approval. Ordering now will deliver the course prior to the formal release date to be announced and lock in the Pre-Sale price.
Peptides, IVs, GLP-1s and the Wellness Frontier
- Accredited CME pending: ACCME / AMA PRA Category 1 Credit™ with AAPA reciprocity and ANCC contact hours, including pharmacology hours (AANP pending, hours to be announced. Currently applied for 11.5 total hours and 6.5 pharmcotherapeutic hours).
This is the only training with ACCME/AMA and ANCC credit. That means both an RN/NP and her medical director can both take this certification course. - Complete GLP-1 weight loss training: workup, prescribing, titration, counseling, and maintenance for semaglutide and tirzepatide from first visit to long-term care
- Peptide evidence and eligibility: the top 20+ marketed peptides, real human data, 503A Bulks List status, and what a risk-averse practice should stock
- Emerging agents covered: retatrutide, oral semaglutide, and orforglipron, because knowing every option matters the moment it reaches your patients
- IV therapy done right: legitimate indications, patient screening, G6PD safety, additives, and the legal and marketing framework
- Scope, compliance, and liability: RN, NP, PA, and medical director roles, good-faith exams, documentation, and cash-pay practice design
- Part of the Beyond Injectables™ suite: alongside BHRT, the full Medical Weight Loss course, Neurotransmitter and GI Health, and a new Non-Injection Aesthetics course for nurses arriving in 2027
- 2 Years of streaming online course access. Watch at your own pace. Complete the post-test and print your CME accredited certificate at home. All course updates in this rapidly changing field are included at no charge for 2 years.
🛒PRE-REGISTER NOW: Peptides, IVs, GLP-1s, and the Wellness Frontier
📃 Peptides, IVs, GLP-1s Full Course Outline
Peptides, IV Hydration, GLP-1s and the Wellness Frontier
The Beyond Injectables Series · Detailed Course Outline
Accreditation: This activity has applied for 11.5 hours ACCME / AMA PRA Category 1 Credit™, with AAPA reciprocity for physician assistants and 11.5 ANCC contact hours (including 6.5 pharmacology hours) for nurses and nurse practitioners. Final credit hours to be determined prior to course release on September 1, 2026.
Format & depth: Online enduring material · approximately 11.5 hours of instruction across ten modules, spanning peptides, medically supervised GLP-1 weight loss, and elective IV therapy.
1. Stress, Nutrition, and the Unforced Errors Behind Common Symptoms ~50 min
- How everyday modifiable inputs drive fatigue, weight gain, poor sleep, and low libido
- The HPA axis and chronic stress: the cortisol rhythm, sleep, dehydration, alcohol, stimulants, and processed food
- Ultra-processed food, gluten, and dairy: the gut microbiome, inflammation, and the blood-sugar response
- Dietary supplements and caffeine in the wellness work-up
- Behavior-change counseling as billable clinical value
2. Scope, Venue, and the Legal Framework for Nurses, NPs, PAs, and Medical Directors ~55 min
- RN, NP, and PA scope of practice for IV therapy, peptides, and GLP-1 prescribing
- Full practice authority, supervision models, and the good-faith examination (synchronous and asynchronous telehealth)
- Standing orders and protocols as the mechanism for RN delivery
- 503A and 503B compounding and legal product sourcing
- HIPAA in cash-pay practice, documentation, and charting standards
- Venue options: clinical office, salon suite, shared medical office, and mobile or in-home
3. Peptides: History and the Compounding Pharmacy Channel ~25 min
- How compounding became a sales channel, from the craft-pharmacy baseline through the telehealth era
- The GLP-1 shortage era, the expansion of compounding, and its conclusion
- The four categories: FDA-approved drug, compounded preparation, research chemical, and dietary supplement
- Decoding supplier marketing: cGMP, purity, and endotoxin claims
- Supplier due diligence and the questions every purchaser should ask
4. The Top 20 Peptides: Evidence, Eligibility, and Regulatory Status ~1.5 hrs
- An evidence review of the twenty most-marketed peptides: human trials versus animal and anecdotal data
- Compound-by-compound coverage of BPC-157, TB-500, Sermorelin, CJC-1295, Ipamorelin, Tesamorelin, AOD-9604, GHK-Cu, Thymosin alpha-1, MOTS-c, Epitalon, KPV, Semax, Selank, DiHexa, PT-141 (Bremelanotide), Melanotan-II, methylene blue, NAD+, NR, NMN, TUDCA, and collagen peptides
- Growth hormone secretagogues, tissue-repair peptides, and cosmetic and sexual-health agents
- The FDA Bulks List, Categories 1 and 2, and the 2026 advisory-committee updates
- A decision framework you can apply to any new compound
5. GLP-1 Weight Loss in Clinical Practice: Semaglutide, Tirzepatide, and the Full Protocol ~2 hrs
- Semaglutide versus tirzepatide: Wegovy, Zepbound, Ozempic, and Mounjaro, mechanisms, dosing, and pivotal trial data
- Candidate selection, contraindications (medullary thyroid carcinoma, MEN2), baseline labs, and pregnancy screening
- Titration, dose holds, side-effect management, and long-term maintenance
- Visit-by-visit counseling: the menu, muscle preservation, and the slow responder
- Cash-pay design, self-pay pharmacies, and prior authorization
6. Emerging Weight-Loss Agents, Including Retatrutide and Oral GLP-1s ~50 min
- Retatrutide: the triple-agonist mechanism and the TRIUMPH program
- Oral GLP-1s: oral semaglutide (Rybelsus, oral Wegovy) and orforglipron (Foundayo)
- Cagrilintide, CagriSema, survodutide, amylin analogs, and combination therapy, plus Lorcaserin, Tesofensine, SLU-PP-332, BAM-15, and 5-Amino-1MQ
- Reading pipeline data: pivotal readouts, effect size, and safety signals
- Participating in clinical trials individually or as a clinic
7. Elective IV Therapy: History, Legal Framework, and Patient Screening ~35 min
- Intravenous therapy and its role in wellness practice, from the Myers cocktail forward
- The evidence base for vitamin drips, hangover IVs, and NAD+ infusions
- The legal and regulatory framework, including Jenifer’s Law (Texas HB 3749) and national trends
- Patient screening, informed consent, and marketing guidelines
8. Elective IV Therapy Done Right: Additives, Compounding, and Administration ~3 hrs
- Patient screening, pre-screening to prevent complications, and what labs can and cannot tell you
- The complete additive menu, reviewed for dosing, evidence, and safety: B-complex, B12, vitamin C, magnesium, calcium, glutathione, NAD+, and more
- Base fluids, IV technique, monitoring, and patient positioning
- Compounding standards, including USP guidance, and bag preparation
- Menu formulations and the elements of a properly documented IV order
9. The Medical Director Role, Oversight, and Practice Ownership ~35 min
- What the supervising physician signs: delegated authority and the oversight chain
- Medical director qualifications, licensure, and supervision models
- Documentation that demonstrates genuine oversight
- Ownership, the corporate practice of medicine (CPOM), and the management services organization (MSO) structure
- Employment versus ownership considerations
10. Synthesizing the Services into an Integrated Wellness Practice ~15 min
- Integrating all three service lines into one coherent practice model
- A decision framework for every service you offer
- The compliant business model, subscription, and membership design
- The provider-patient partnership and trust as a retention strategy
- The bridge to companion training in aesthetics, hormone therapy (BHRT), and weight loss
❓ About the Beyond Injectables™ CME Training Series
Beyond Injectables™ is PracticalCME’s suite of fully accredited online CME training courses designed for busy nurses, nurse practitioners, and physician assistants who want to enter the most in-demand wellness and aesthetic services, and who demand the most rigorous, evidence-based, MD-taught training before doing so. For over 18 years, PracticalCME has been a leader in small-group, physician-led training in injectable procedures like Botulinum Toxin, Dermal Fillers, PRP, and Microneedling. As our students have gone on to successful careers, many want the same level of training for non-aesthetic and non-injectable services so they can better treat patients inside and out. Every course is vendor-neutral, evidence-based, and accredited for ACCME / AMA PRA Category 1 Credit™ with AAPA reciprocity and ANCC contact hours, including pharmacology hours. The series includes:
- Peptides, IVs, GLP-1s and the Wellness Frontier — comprehensive training in GLP-1 weight loss (semaglutide, tirzepatide), peptide therapy, IV wellness practice, and compounding law (this course, to be released September 2026)
- Saliva Testing and Bio-Identical Hormone Therapy (BHRT) — hormone optimization, saliva testing, and treatment of fatigue, low libido, and menopause symptoms (available now, revision planned Q3 2026)
- Evidence-Based Weight Loss and GLP-1 Master Course — the complete deep-dive into medical weight loss, GLP-1 prescribing, and long-term patient management (available now, revision planned Q1 2027)
- Neurotransmitter and GI Testing and Treatment — the gut-brain axis, neurotransmitter testing, stress, and GI health protocols (available now, revision planned Q2 2027)
- Non-Injectable Aesthetics for Nurses — evidence-based aesthetic services including chemical peels, microdermabrasion, and dermaplaning (new course planned for Q4 2026)
Every Beyond Injectables™ course is taught by a board-certified physician and built on the same principle: clinical judgment first, sound business practice second, and no vendor hype. Whether you are an RN, NP, or PA launching a cash-pay wellness clinic or a medical director evaluating what your practice should safely offer, this series delivers the accredited, up-to-date training you need to practice confidently and defensibly in 2026 and beyond.
🏅CME Accreditation Application Statement
- Peptides, IVs, GLP-1s and The Wellness Frontier
- This course has applied for ACCME, AMA Category 1, and ANCC credit with pharmacology hours. (number of credits to be determined)
- Anticipated dates: September 1, 2026 through September 1, 2028 (to be determined)
⏩ About Our Interactive Online Training
First, Reserve your Online Training Seat in any Beyond Injectables Aesthetic or Wellness Training Course.
You will have 2 Years of Unlimited Online Access wtih Free Updates pushed to your account periodically as needed and new drugs are approved.
Then Watch the Online training at your own pace. Follow clickable links and interact with our faculty for any questions you have. When finished, complete the online post-test.
DOWNLOAD/PRINT CME CERTIFICATE
⭐⭐⭐⭐⭐ PracticalCME Wellness Course Reviews
No training course alters the legal scope of practice as defined by the medical/nursing boards in your home state/country. Please review all state/country requirements for supervision for these procedures prior to adding them to your practice.
Frequently Asked Questions
What does this GLP-1 and peptide CME course cover?
The course covers medical weight loss with GLP-1 medications including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), the top 20 marketed peptides, IV wellness therapy, and emerging agents such as retatrutide, oral semaglutide, and orforglipron. It teaches candidate selection, contraindication screening, prescribing and titration, patient counseling, compounding law (503A and 503B), scope of practice, and medical director liability.
Is this course accredited for CME and CE credit?
Yes. The activity is designed for ACCME / AMA PRA Category 1 Credit™ with AAPA reciprocity for PAs and ANCC contact hours for nurses and nurse practitioners, including pharmacology hours. This is genuine accreditation in a field that too often runs on vendor marketing, rumor, and hearsay. Credit hours will be announced once finalized by September 1, 2026.
Who should take this course?
Registered nurses, nurse practitioners, physician assistants, and physicians serving as medical directors of wellness, weight loss, aesthetic, or IV therapy clinics. It is built for clinicians who want evidence-based, vendor-neutral training before offering GLP-1 weight loss, peptide therapy, or IV services.
Does the course teach how to prescribe and dose GLP-1 medications?
Yes. It walks through the full clinical workup, baseline labs, contraindication screening, starting doses, the escalation schedule, dose holds, maintenance dosing, side-effect management, and visit-by-visit patient counseling for semaglutide and tirzepatide, plus the oral GLP-1 options.
Does it cover retatrutide and other emerging weight-loss agents?
Yes. Because CME is education, the course covers retatrutide, oral semaglutide, and orforglipron so clinicians understand every therapy patients ask about and are prepared as these agents reach the market. It also teaches how to respond to patients requesting agents that are not yet FDA-approved.
Does the course explain peptide compounding law and the top marketed peptides?
Yes. It reviews the 20 most-marketed peptides with their real human evidence, the 503A Bulks List status, and WADA considerations, and it explains the difference between an FDA-approved drug, a compounded preparation, a research chemical, and a supplement, including how to decode supplier marketing.
Does it cover IV therapy and vitamin drips?
Yes. The course covers what IV hydration and vitamin infusions do and do not do, legitimate medical indications, patient screening, G6PD safety before high-dose vitamin C, defensible additives, and the legal and marketing framework for an IV wellness practice.
Is the course online and self-paced?
Yes. It is a fully online, self-paced video training course from PracticalCME, taught by a board-certified physician, and accessible on demand from any device.
Does it address scope of practice and medical director liability?
Yes. It covers RN, NP, and PA scope for these services, standing orders, the good-faith exam and telehealth rules, documentation that protects the practice, and what a supervising physician is exposed to when signing on as medical director.